Many factors contribute to delays in vaccine market access including, but not limited to, poorly transparent National Immunization Technical Advisory Group (NITAG) processes and requirements, time-consuming evidence-generation requirements, and gaps and uncertainties in the evidence base.
We have launched a “100 days to vaccine market access” initiative to help vaccine manufacturers submit NITAG/HTA packs within 100 days of marketing authorization. Our recommendations focus on the implementation of a three-pillar framework, which can be used to address HTA/NITAG submission requirements and overcome challenges across the vaccine life cycle.
What you will learn in this white paper:
• Insights to overcome barriers to timely vaccine market access
• Our three-pillar strategy for successful evidence generation across the vaccine life cycle
• Strategies to expedite patient access to vaccines
Complete the form to access the white paper.